Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig J Thomas

Showing results (191-200 of 227) with videos related to

Pageof 23
Sort By:
Science Translational Medicine|July 6, 2018
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcomaMarielle E Yohe, Berkley E Gryder, Jack F Shern, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate CancerJessica D Kindrick, Kinjal Bhadresha, Xiaohu Zhang, et al.
Genome Medicine|August 25, 2016
Cancer network activity associated with therapeutic response and synergismJordi Serra-Musach, Francesca Mateo, Eva Capdevila-Busquets, et al.
Cancer Discovery|April 28, 2017
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain VulnerabilityBerkley E Gryder, Marielle E Yohe, Hsien-Chao Chou, et al.
Molecular Cancer Therapeutics|November 7, 2020
Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and NeuroblastomaJoshua T Kowalczyk, Xiaolin Wan, Edjay R Hernandez, et al.
Cancers|August 26, 2023
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaJerry T Wu, Adam Cheuk, Kristine Isanogle, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid LeukemiaScott B Hoyt, Chris J Finocchio, Elizabeth Croll, et al.
Plos One|July 16, 2015
Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of AssaysJonathan A Lee, Paul Shinn, Susan Jaken, et al.
Nature Communications|June 23, 2023
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complexYilun Sun, Simone A Baechler, Xiaohu Zhang, et al.
Science Translational Medicine|September 6, 2019
Overcoming adaptive therapy resistance in AML by targeting immune response pathwaysKatelyn Melgar, Morgan M Walker, LaQuita M Jones, et al.
Pageof 23

Showing results (191-200 of 227) with videos related to

Sort By:
Pageof 23
Science Translational Medicine|July 6, 2018
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcomaMarielle E Yohe, Berkley E Gryder, Jack F Shern, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Co-Targeting Nuclear Export and Translation Initiation Uncovers a Therapeutic Vulnerability in Lethal Prostate CancerJessica D Kindrick, Kinjal Bhadresha, Xiaohu Zhang, et al.
Genome Medicine|August 25, 2016
Cancer network activity associated with therapeutic response and synergismJordi Serra-Musach, Francesca Mateo, Eva Capdevila-Busquets, et al.
Cancer Discovery|April 28, 2017
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain VulnerabilityBerkley E Gryder, Marielle E Yohe, Hsien-Chao Chou, et al.
Molecular Cancer Therapeutics|November 7, 2020
Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and NeuroblastomaJoshua T Kowalczyk, Xiaolin Wan, Edjay R Hernandez, et al.
Cancers|August 26, 2023
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric RhabdomyosarcomaJerry T Wu, Adam Cheuk, Kristine Isanogle, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid LeukemiaScott B Hoyt, Chris J Finocchio, Elizabeth Croll, et al.
Plos One|July 16, 2015
Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of AssaysJonathan A Lee, Paul Shinn, Susan Jaken, et al.
Nature Communications|June 23, 2023
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complexYilun Sun, Simone A Baechler, Xiaohu Zhang, et al.
Science Translational Medicine|September 6, 2019
Overcoming adaptive therapy resistance in AML by targeting immune response pathwaysKatelyn Melgar, Morgan M Walker, LaQuita M Jones, et al.
Pageof 23